nivolumab
bms
['sclc', 'opdivo', 'lung', 'nsclc', 'bristol']
 after two years, 32.5% of the lung cancer patients with kras g12c-mutated nsclc were alive, a result which compares favorably to historical data from bristol myers squibb s pd-1 inhibitor opdivo.